← Back to Calendar
Live Company Data
NGM
Updated
1m ago
· Data: FMP
Current Price
$19.39
+83.97%
+$8.85 today
Day: $19.14 – $19.98
Market Cap
N/A
Shares out: 51.22M
Float: 29.56M
52-Week Range
Current price is at 83% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Hereditary angioedema (HAE) — on-demand oral treatment
Key Notes
First oral on-demand treatment for HAE attacks from KalVista's pipeline (distinct from EKTERLY/sebetralstat which launched in July 2025). ZENITH-1 and ZENITH-2 Phase 3 data. Note: EKTERLY (sebetralstat) is KalVista's already-approved HAE drug; donidalorsen is a separate NDA submission.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.